Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24707902 | 1.00 | NR1H2 (0.49) | NR1H2USP2SMN1; SMN2PDE4BRECQL | |
| SCHEMBL10137666 | 1.00 | NR1H2 (0.49) | NR1H2USP2SMN1; SMN2PDE4BRECQL | |
| SCHEMBL10137667 | 1.00 | NR1H2 (0.49) | NR1H2USP2SMN1; SMN2PDE4BRECQL | |
| SCHEMBL10137713 | 1.00 | NR1H2 (0.49) | NR1H2USP2SMN1; SMN2PDE4BRECQL | |
| SCHEMBL25608131 | 1.00 | NR1H2 (0.49) | NR1H2USP2SMN1; SMN2PDE4BRECQL | |
| SCHEMBL6065186 | 0.91 | NR1H2 (0.53) | NR1H2USP2SMN1; SMN2PDE4BRECQL | |
| SCHEMBL1052921 | 0.91 | NR1H2 (0.53) | NR1H2USP2SMN1; SMN2PDE4BRECQL | |
| SCHEMBL1051376 | 0.91 | NR1H2 (0.53) | NR1H2USP2SMN1; SMN2PDE4BRECQL | |
| SCHEMBL10585442 | 0.88 | NR1H2 (0.45) | NR1H2USP2SMN1; SMN2PDE4BRECQL | |
| SCHEMBL10054586 | 0.86 | NR1H2 (0.49) | NR1H2USP2SMN1; SMN2PDE4BRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240390383-A1 | DIOXAZINES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES | Zevra Denmark A/S (DK) | 2024-11-28 | — | — | US | disclosed |
| EP-4408838-A1 | DIOXAZINES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES | Zevra Denmark A/S (DK) | 2024-08-07 | — | — | EP | disclosed |
| CN-118076599-A | Dioxazines and their use in the treatment of GBA related diseases | 泽拉丹麦有限公司 | 2024-05-24 | — | — | CN | disclosed |
| WO-2023053007-A1 | DIOXAZINES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES | KEMPHARM DENMARK A/S (DK) | 2023-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240390383-A1 | DIOXAZINES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES | GBA1, GBA2, GBA3 | NR1H2 465/4885USP2 2118/4885SMN1; SMN2 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.